Department of Pharmacology, Heymans Institute, De Pintelaan 185, B-9000 Ghent, Belgium.
Eur J Clin Pharmacol. 2011 Jan;67(1):11-7. doi: 10.1007/s00228-010-0926-y. Epub 2010 Nov 16.
The importance of tocolysis has been discussed extensively. Beta-2 adrenoceptor agonistic drugs like ritodrine have been the reference tocolytic drugs in most countries. Cardiovascular side-effects are frequent. Atosiban, a newer tocolytic drug, is a competitive antagonist of oxytocin and has fewer cardiovascular side effects. Although large studies exist, there is mainly subjective reporting of adverse reactions with a focus on blood pressure data.
Evaluation of the acute effects of therapeutic doses of ritodrine and atosiban in comparison to placebo on central and peripheral blood pressures, central-to-peripheral blood pressure amplification and the augmentation index (AIx) in healthy non-pregnant female volunteers.
A double-blind, randomized, crossover trial was carried out in 20 healthy non-pregnant female volunteers. Hemodynamic measurements were performed under standardized conditions.
At steady state, central and peripheral pressures did not differ from placebo in the atosiban group. During ritodrine -infusion, central SBP increased by 11% versus placebo (p = 0.012) and peripheral SBP by 10% (p = 0.004). In contrast to atosiban and placebo, blood pressure amplification was absent in the ritodrine group. While the AIx did not change in the atosiban group, with ritodrine, the AIx tended to decrease.
The present study shows the significant effects of ritodrine on the cardiovascular system. Atosiban has no significant effects and may be an appropriate alternative to tocolyticum, particularly in cardiovascularly complicated pregnancies.
关于保胎的重要性已经有了广泛的讨论。β-2 肾上腺素能激动剂，如利托君，在大多数国家都是参考保胎药物。然而，此类药物会引起心血管副作用。阿托西班，一种新型保胎药物，是催产素的竞争性拮抗剂，心血管副作用较少。尽管已有大量研究，但不良反应的报告主要是主观的，重点是血压数据。
评估治疗剂量的利托君和阿托西班与安慰剂相比对健康非妊娠女性志愿者的中心和外周血压、中心至外周血压放大和增强指数（AIx）的急性影响。
在 20 名健康非妊娠女性志愿者中进行了一项双盲、随机、交叉试验。在标准化条件下进行血流动力学测量。
在阿托西班组，稳态时中心和外周血压与安慰剂相比无差异。在利托君输注期间，中心 SBP 比安慰剂增加 11%（p = 0.012），外周 SBP 增加 10%（p = 0.004）。与阿托西班和安慰剂不同，利托君组没有血压放大。阿托西班组的 AIx 没有变化，而利托君组的 AIx 则有下降趋势。
本研究显示利托君对心血管系统有显著影响。阿托西班没有显著影响，可能是保胎药物的替代选择，特别是在心血管复杂的妊娠中。
